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Abstract: Cardiovascular disease (CVD) and type 2 diabetes (T2D) remain the top disease and
mortality burdens worldwide. Oats have been shown to benefit cardiovascular health and improve
insulin resistance. However, the evidence linking oat consumption with CVD, T2D and all-cause
mortality remains inconclusive. We conducted a comprehensive systematic review and meta-analysis
of prospective cohort studies to evaluate the associations between oat consumption and risks of T2D,
CVD and all-cause mortality in the general population. Five electronic databases were searched until
September, 2020. Study specific relative risks (RR) were meta-analyzed using random effect models.
Of 4686 relevant references, we included 9 articles, based on 8 unique studies and 471,157 participants.
Comparing oat consumers versus non-consumers, RRs were 0.86 (95% CI 0.72–1.03) for T2D incidence
and 0.73 (95% CI 0.5–1.07) for combined CVD incidence. Comparing participants with highest versus
lowest oat intake, RRs were 0.78 (95% CI 0.74–0.82) for T2D incidence, 0.81 (95% CI 0.61–1.08) for
CHD incidence and 0.79 (95% CI 0.59–1.07) for stroke. For all-cause mortality one study based
on three cohorts found RR for men and women were 0.76 (95% CI 0.69–0.85) and 0.78 (95% CI
0.70–0.87), respectively. Most studies (n = 6) were of fair to good quality. This meta-analysis suggests
that consumption of oat could reduce the risk for T2D and all-cause mortality, while no significant
association was found for CVD. Future studies should address a lack of standardized methods in
assessing overall oat intake and type of oat products, and investigate a dose-dependent response
of oat products on cardiometabolic outcomes in order to introduce oat as preventive and treatment
options for the public.
Keywords: oat; type 2 diabetes; cardiovascular disease; mortality
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1. Introduction
Oats (Avena sativa) are a whole-grain cereal predominantly grown in Europe and
the Americas [1]. They are recognized for their fiber content, especially beta-glucan, and
are a rich source of many vitamins and minerals, and have the highest protein content
among cereals and other bioactive compounds [2]. Whole oats contain over 20 unique
polyphenols, such as avenanthramides, which have demonstrated strong antioxidant
activity in vivo and in vitro [3]. Due to their potential health benefits, oat consumption
is increasing in the western world. Although oatmeal (thinly cut whole grain oats) is
consumed worldwide, the primary markets are North America and North Europe [1]. Carl
von Noorden, a German physician and diabetologist, reported the first therapeutic effects
of oats—the attenuation of blood glucose levels—in 1903 [4]. Since then, oats have been
shown to improve insulin sensitivity [5], glucose metabolism [6–8], blood lipid profile [9],
endothelial function [10] and inflammation [11], all important markers associated with
the development of type 2 diabetes (T2D), cardiovascular disease (CVD) and all-cause
mortality. However, the association of oat intake with cardiometabolic disease and all-cause
mortality in longitudinal observational studies remains inconsistent. Several studies have
found inverse associations between oat consumption and impaired glucose metabolism in
T2D [8,12], markers of CVD [13] and all-cause mortality [14], while others have reported
no associations [15,16].
To find a consensus, a comprehensive analysis of the literature is needed. We, therefore,
undertook a systematic review and meta-analysis of prospective studies to explore the
associations of oat consumption with the risk of T2D, CVD and all-cause mortality in the
general population.
2. Materials and Methods
We performed a systematic review and meta-analysis in accordance with a recently
published guideline on conducting a systematic review and meta-analysis, as well as the
PRISMA guidelines [17,18]. The protocol for the current study is registered in PROSPERO
(ID:CRD42020196084).
2.1. Data Source and Strategy
We searched MEDLINE via Ovid, EMBASE, Web of Science Core Collection, Cochrane
Library, and Google Scholar to identify relevant articles. Search terms included subject
headings and free text words related to oat consumption (oat, oat bran, oatmeal, porridge,
oat cereal, oat bran beta-glucan, oat whole grains) and adverse outcomes including incident
CVD (coronary heart disease, heart failure, coronary artery disease, myocardial ischemia,
stroke, myocardial infarction, cardiovascular/coronary heart disease death, fatal stroke),
incident T2D and all-cause mortality. We searched the databases from inception until 18th
September 2020. We limited our search to human studies. No limitations on publication
date or language were used. We additionally searched the references of eligible articles
and studies that have cited those articles. The complete search strategy is outlined in the
Appendix A.
2.2. Study Selection and Eligibility Criteria
Studies were included if they (i) were of prospective design (nested case-control
studies, case-cohort studies, prospective cohort studies and clinical trials); (ii) had reported
on oat intake as part of the diet or as supplements, and (iii) had provided information on the
association between oat intake/supplementation with risk of T2D, CVD and/or all-cause
mortality. We excluded abstracts, cost-effectiveness studies, letters to the editor, conference
proceedings, cross-sectional studies, case-control studies other than those of prospective
design (e.g., nested case-control studies), systematic reviews, and meta-analyses. Studies,
among adults, examining the association between oat consumption (not overall wheat)
and outcomes of interest were included.
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2.3. Data Extraction
The titles and abstracts were screened by two independent reviewers in accordance
with the selection criteria (FW and PET). A data extraction form was used to record
information such as the author’s name, study location, study design, sample size, baseline
age, follow-up time, methods used to assess oat intake, outcome definition, number of
events, measures of associations, and level of adjustment. Before beginning the full data
extraction, the form was developed, piloted, and discussed within the review group. When
multiple publications were assessed, the most recent or comprehensive information was
used. Extracted data are summarized in Tables S2–S4.
2.4. Risk of Bias Assessment
The quality of included studies was independently assessed by two authors (FW and
PET) using the Newcastle–Ottawa Scale for cohort studies [19]; a third author (TM) adjudi-
cated if consensus could not be reached. The scale was developed for non-randomized and
observational studies and assesses quality in three broad categories: study group/participant
selection, group/participant comparability, and the assessment of exposure/outcome of
interest. Quality was graded on a 10-point scale and classified as good (8–10 points), fair
(5–7), or poor (<5). In addition, we used the Grading of Recommendations Assessment, De-
velopment and Evaluation (GRADE) method to assess the quality of evidence in the current
review. The GRADE method evaluates evidence based on two key concepts: magnitude
of effect and quality of evidence (considering the risk of bias, study design, consistency
and directness of findings). The evidence is categorized as either high, moderate, low or
very low. RCTs begin with high quality, whereas observational studies begin with low
quality. Study limitations, significant inconsistency of results, or uncertainty about the
directness of the evidence can all lower the grade of evidence. Furthermore, evidence of a
dose response gradient or strong evidence of association based on consistent evidence from
two or more observational studies with no plausible confounders may raise the grade [20].
Two reviewers worked independently on the evaluation, and any disagreements were
resolved through discussion between the two parties or by bringing in a third reviewer.
2.5. Data Synthesis and Analysis
We calculated pooled relative risks (RR) and 95% confidence intervals (CI) for incident
CVD, incident T2D, and all-cause mortality between oat consumers and non-consumers,
and highest vs. lowest oat intake based on the extracted data from each study. Odds ratios
reported by Xu X. et al., 2019 were converted to relative risks using the method described
by Grant R, 2014 [21].
The inverse variance weighted method was used to combine RR to produce a pooled
RR using random-effects models to account for between-study heterogeneity; as a sensi-
tivity analysis, we reported the estimates derived from fixed effect models. Fixed effect
models, on the other hand, were used to pool results from different groups in the same
study, which were then included in our meta-analyses. For meta-analyses including 4 or
more studies, we also assessed publication bias by funnel plot, and Egger’s test was used to
assess asymmetry. All analyses were conducted with STATA 16.1 (StataCorp. 2019. College
Station, TX, USA: StataCorp LLC.). We calculated 2-tailed tests and a p-value <0.05 was
considered significant.
3. Results
3.1. Study Identification and Selection
A total of 4686 citations were identified, of which 30 were chosen for full-text eval-
uation (Figure 1). Of those, 9 articles based on a total of 8 unique studies reporting on
471,157 participants were included with relevant available data on T2D (5 studies), CVD
(7 studies), and all-cause mortality (3 studies). Table 1 summarizes the detailed character-
istics of the included studies. Of these, 3 were based in North America, 3 in Europe, and
2 in the Asia-Pacific region. All studies were prospective cohort studies. The follow up
Nutrients 2021, 13, 2560 4 of 15
time ranged between 2.2 and 30 years. Most studies (n = 6) were of fair to good quality
(score ≥ 7), while 2 studies were of poor quality (score < 5). The assessed oat intake varied
between the studies: 3 studies analyzed oatmeal consumption, 1 investigated oatmeal and
whole grain oat intake, 1 article assessed the effects of oat fiber from various oat containing
products [22], 1 study analyzed specifically oat cereals [23], and 2 looked only at whole
grain oats [24]. No study had reported investigating associations with oat extracts. Table S1
contains information on the specific characteristics of the studies that were included.
Figure 1. PRISMA flow diagram of search strategy.
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Table 1. Summary of the studies included in the systematic review.
Reference Study Location Cohort Name No. ofIndividuals










T2D CVD All-Cause Mortality
Helnaes (2016) [25] Denmark
Danish Diet, Cancer, and Health
cohort (DCH) 54871
all m 1: 25921: 55.0 (50.0–64.0)
47.2 13.6 median oatmeal 1 NA 2329 NA 8
cases m: 1676: 57.0 (51.0–64.0)
all w 1: 28950: 56.0 (50.0–64.0)
cases w: 653: 59.0 (51.0–64.0)
Hu (2020) [26] US
Nurses’ Health Study (NHS) 69139 mean 30 0
24 mean oatmeal NA
9723
NA NA 7
Nurses’ Health Study II (NHSII) 89120 0 6821
Health Professionals Follow-up
Study (HPFS) 36525 100 2085
Johnsen (2015) [24]








298 women, 858 men
died from CHD 3,




Norway the Norwegian Women andCancer Study 37111 0 11.1 median NA 966
Sweden the Vasterbotten InterventionProgramme cohort 25551 48.3 14.2 median NA 1367
Denmark the Danish Diet Cancer andHealth Study 56865 47.6 11.9 median NA 5506
Juan (2017) [27] US
Health Professionals Follow-up
Study 42823 mean (SD) 53.2(9.5) 100 24
oatmeal NA NA NA
908
7
Nurses’ Health Study 71750 mean (SD) 50.1(7.1) 0 26 1550
Kyro (2018) [28] Denmark Diet, Cancer, and Health cohort 55465 50–65 47.3 15 whole grainoat, oatmeal 1 7417 NA NA 9
Liu (2000) [29] US Nurses’ Health Study 75521 38–63 mean 0 10 oatmeal NA 1879 NA NA 7
Lyskjaer (2020) [30] Denmark Diet, Cancer, and Health cohort 55095 56.1(52.7–60.3) 47.6 13.4 median oatmeal 0.7 NA 2260 NA 8
Olsen (2011) [14] Denmark Diet, Cancer, and Health cohort 57053 50–64 46.3 12 oatmeal 0.8 NA NA 4126 9
Xu (2019) [23] Australia 45 and Up Study 142503
45–64y 37,626 all cases




Wu (2019) [22] Taiwan The Biosignature study 1663 mean ± SD nouse:65.26 ± 12.19oat:68.82 ± 11.65 36.6






NA NA 175 N/A 6
1 m–number of men and w–number of women in the study. 2 HELGA cohort consists of The Norwegian Women and Cancer Study, The Northern Sweden Health and Disease Study and The Danish Diet, Cancer
and Health Cohort Study. 3 CHD–coronary heart disease.
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3.2. Association between Oat Consumption and Risk of Type 2 Diabetes
Five studies [23,26,28,29] were included in the meta-analysis of oat consumption and
incidence of type 2 diabetes (Table 1). We previously excluded one article, since it was based
on the Danish Diet, Cancer and Health cohort and the analysis was done earlier and on a
smaller number of participants than another study [31] (Table S2). The studies included
a total of 31,329 incident cases of T2D. The total duration of follow-up ranged from 6 to
30 years. All studies excluded patients with T2D diagnosis at baseline and adjusted for
age, physical activity, smoking, alcohol consumption and body mass index. Three studies
additionally adjusted for total energy intake; two also adjusted for use of multivitamins,
family history of diabetes, educational level, red meat consumption and postmenopausal
hormone use for women. One study also adjusted for dietary fiber consumption, ethnicity
and marital status.
Higher oat intake (more than 5.7 g/day) was significantly associated with lower risk
of T2D when compared to lower consumption (less than 1.3g/day), with a relative risk of
0.78 (95% confidence interval 0.74 to 0.82; I2 = 47%, p = 0.129) (Figure 2).
Figure 2. The association between oat consumption and risk of type 2 diabetes. Participants with highest vs. lowest oat
consumption are compared. I-V: inverse-variance estimation, random effect model. D + L: DerSimonian–Laird (DL) method,
fixed effect model [32].
Dietary intake of oats was associated with a lower risk of T2D with a relative risk
of 0.86, albeit not statistically significant (95% confidence interval 0.72 to 1.03; I2 = 97.6%,
p < 0.001) (Figure 3). There was evidence of heterogeneity in T2D estimates across studies
for oat consumption. Two studies using data from the Danish Diet, Cancer and Health
cohort reported that men and women consuming >21 g/day of oatmeal/muesli had a lower
risk of developing T2D (21–27% decreased risk in the more recent study) (data from [28]).
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Figure 3. The association between oat consumption and risk of type 2 diabetes. Consumers vs. non-consumers are compared.
I-V: inverse-variance estimation, random effect model. D + L: DerSimonian–Laird (DL) method, fixed effect model [32].
3.3. Association between Oat Consumption and Risk of Cardiovascular Disease
Seven studies [22–25,27,30] were included in the meta-analysis of oat consumption
and risk of cardiovascular disease. Three articles, including the Danish Diet, Cancer, and
Health (n = 1) cohort and the Nurses’ Health Study cohort (n = 2), were excluded since new
studies on the same cohorts analyzing the same outcomes were included in the analysis
(Table S2). The meta-analysis included 18,128 cases of cardiovascular disease, coronary
heart disease, myocardial infarction, or stroke from seven contributing studies. The total
duration of follow-up ranged from 6 to 26 years. All included studies adjusted for age and
smoking, six studies additionally adjusted for alcohol consumption, physical activity and
body mass index, four studies additionally adjusted for education and hypertension, and
three for cholesterol, total energy intake and menopausal status and hormone therapy for
women. Two studies additionally adjusted for gender, ethnicity and diabetes history.
No significant associations were found between oat intake as a continuous dietary
exposure and risk of coronary heart disease and myocardial infarction combined together,
or stroke with relative risks of 0.81 (95% confidence interval 0.61 to 1.08; I2 = 99.2%,
p = 0.000) and 0.79 (95% confidence interval 0.59 to 1.07; I2 = 97.2%, p = 0.000), respectively
(Figure 4a,b). Dietary intake of oats was also not associated with the risk of composite
cardiovascular diseases (relative risk 0.73, 95% confidence interval 0.5 to 1.07; I2 = 78.9%,
p = 0.029; Figure 4c). There was evidence of heterogeneity in cardiovascular disease esti-
mates across studies for oat consumption.
3.4. Association between Oat Consumption and All-Cause Mortality
We found two articles reporting the effects of oats on all-cause mortality, with an
overlapping cohort (Danish Diet, Cancer, and Health cohort; [14,24]). We included the
most recent study in our analysis. In total, one article describing three individual cohorts
investigated the association between oat intake and all-cause mortality, with 7839 cases of
all-cause mortality. The median follow-up duration ranged from 11.1 to 14.2 years in these
prospective studies. The study adjusted for age, follow up time, education, smoking inten-
sity, alcohol intake, BMI and total energy intake. When comparing participants with higher
vs. lowest oat intake, both men and women with highest consumption (>19 g/day) had
significantly lower risks for all-cause mortality with a relative risk of 0.76 (95% confidence
interval 0.69 to 0.85) and 0.78 (95% confidence interval 0.7 to 0.87), respectively.
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Figure 4. The association between oat consumption and risk of cardiovascular disease. (a). The association between oat
consumption and risk of cardiovascular disease. Participants with highest vs. lowest oat consumption are compared.
CHD–coronary heart disease, MI–myocardial infraction. (b). The association between oat consumption and risk of stroke.
Participants with highest vs. lowest oat consumption are compared. (c). The association between oat consumption and
risk of composite cardiovascular disease. Consumers vs. non-consumers are compared. I–V: inverse-variance estimation,
random effect model. D + L: DerSimonian–Laird (DL) method, fixed effect model [32].
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3.5. Study Quality
For risk of T2D and CVD, the results were of low and very low certainty. The evidence
was based solely on the observational data. Despite the fact that the study population
and each outcome showed good generalizability, we found some heterogeneity. We were
unable to investigate the publication bias for other outcomes due to the small number of
studies. There was no evidence of publication bias in the study of oat intake and CVD risk
(p > 0.05, Figure 5). Imprecision, inconsistency and risk of bias were a problem for most
subgroups. Table S5 summarizes the assessment of evidence quality.
Figure 5. Funnel plot for association of oat intake with cardiovascular disease.
3.6. Sensitivity Analysis
The fixed effects models showed significant associations of oat intake (high vs. low)
with incidence of type 2 diabetes, composite cardiovascular disease and stroke ( Figure 2;
Figure 4a,b). Under the fixed effects model, compared to non-consumers, oat consumers




We conducted a systematic review and meta-analysis using data from approximately
471,157 participants from 8 studies to help clarify available evidence on the associations of
oat intake with the risk of type 2 diabetes, cardiovascular disease, and all-cause mortality.
Overall, our findings show that a high oat consumption is associated with a lower risk of
T2D and all-cause mortality, but not consistently with CVD.
4.2. Comparison with Other Studies
To date, this is the first meta-analysis to investigate the association between oat intake
and risk of type 2 diabetes, cardiovascular disease and all-cause mortality. Our findings
are in agreement with multiple published meta-analyses, reporting positive effects of oat
intake on T2D risk factors, such as lowering HbA1c, fasting and postprandial glucose and
fasting insulin [5]. Since oats are considered to be a whole grain, our findings are consistent
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with the previously published data on beneficial effects of whole grains on the risk of
coronary heart disease, CVD, total cancer, and mortality from all causes [33]. Moreover,
whole grain oats appeared to be the most effective whole grain in terms of cholesterol
reduction [34].
4.3. Potential Underlying Mechanisms
Oats deliver high amounts of valuable nutrients, including proteins, minerals, B
vitamins, and iron, but a substantial amount of the beneficial effect is attributed to the
fiber content. Fiber intake in general has been found to be associated with reduced risks
of all-cause mortality, CVD and all cancers [35]. In multiple randomized controlled trials,
fiber consumption decreased LDL cholesterol [36], postprandial glucose and insulin [37],
while some meta-analyses have reported inverse associations between fiber and risk of
metabolic syndrome [38], decrease in BMI, body weight, fasting glucose, fasting insulin [39]
and lower systolic and diastolic blood pressure [40], all risk factors for type 2 diabetes and
cardiovascular disease. The principal component of oat fiber is beta-glucan, a non-digestible
polysaccharide, that cannot be absorbed in the small intestine. Beta-glucan is water-soluble
and increases the viscosity of the alimentary bolus in the upper gastrointestinal tract,
slowing nutrient absorption and thus postprandial glucose excursions [41]. Specifically,
beta-glucan intake from oats has been associated with lower total and LDL cholesterol [9],
lower appetite [42] and higher serum nitric oxide, an important cell signaling molecule
essential for vascular health and lowering blood pressure [43]. Avenanthramides, a unique
type of phenolic compounds present in oats with antioxidant and anti-inflammatory
properties, have also been reported to increase nitric oxide bioavailability and hence
lower blood pressure [10,44]. In addition, a number of clinical trials have also found
that oats improve glucose control [6–8]. Whole oats deliver many bioactive compounds
simultaneously and have shown superior ability to help manage glucose control and
insulin sensitivity when compared to isolated beta-glucans from oats [45]. Oats also have
a high satiety index, together with the releasing effect of the anorexigenic peptide YY by
beta-glucan, which can lead to lower caloric intake and may decrease the risk of obesity [46].
In addition, low calorie diets can have positive effects on diabetes [47] and longevity [48].
Two recently completed clinical trials might shed more light on the mechanism of oat beta-
glucan (NCT04299763), oat bran (NCT03805802) and oat powder (NCT03911427) effects on
T2D and CVD risk factors.
4.4. Strengths and Limitations of the Study
This work’s strengths and weaknesses deserve careful consideration. This is the first
comprehensive meta-analysis using a predefined protocol, investigating the associations of
oat consumption with risk of T2D, CVD and all-cause mortality. The quality of included
studies was good to moderate and the numbers of participants and the analyzed events
were high. Several limitations also warrant mentioning. Because only 9 articles met our
search criteria, we may not have enough power to detect a definite effect in the case of
cardiovascular disease risk. Due to the limited number of studies included in each analysis,
it was also not possible to define the sources of heterogeneity observed in our meta-
analyses. The possible reasons for the null association with CVD could be the difference
in assessed oat intake in different populations: 8 articles analyzed oatmeal consumption,
3 assessed oatmeal and whole grain oat intake, one article assessed the effects of oat fiber
from various oat containing products [22], one study analyzed oat cereals specifically [23],
and one looked only at whole grain oats [24], as well as different questionnaires used for
consumption assessment. Median oat intake also tended to vary between different studies:
from median 0.7 g/day [30] to 2 g/day [24]. The follow-up period of one of the studies
was only 6 years, which might not be long enough for the development of cardiovascular
disease. The results for T2D are mainly based on three large cohort studies conducted
in health professionals in the US, while the results were statistically significant, future
studies analysing effects of oats in other countries/other settings will be beneficial. Because
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the available data for the meta-analysis on oat intake were rather limited, heterogeneity
across studies was high, even though we used random-effects, and studies of oat intake
affecting all-cause mortality were few. Therefore, future large-scale studies would allow
for a more detailed and specific assessment of the relationship between the oat and T2D,
CVD, and all-cause mortality, such as dosage assessment and standardized adjustment
for confounders. (i.e., smoking status, BMI, quality of diet), evaluation of heterogeneity
among diverse study populations. We were only able to conduct analysis on consumers
vs. non-consumers and participants with high vs. low oat intake due to the limited
number of eligible studies. We were not able to address the question of at what dosage the
beneficial effects of oat consumption would trigger the positive outcome. Future studies
should explore whether the association between oat and health outcomes depends on the
quantity of oat consumption. Moreover, since there was only one article based on three
studies which we found eligible to assess the effect of oats on all-cause mortality, we could
not perform a meta-analysis to address this topic. The cohorts in this study are all from
developed Scandinavian counties, and while the findings are promising, more studies from
other counties are required to determine if the results are reproducible. GRADE assessment
indicated that further high-quality randomized trials are needed for a firm conclusion.
4.5. Implications for Clinicians and Policy Makers
Our findings could have significant policy and scientific ramifications. These findings
emphasize the importance of including oats and/or oat products in the diet to reduce the
risk of T2D and possibly CVD (as suggested by the results of fixed effects models) two of the
most common noncommunicable diseases worldwide. Cardiovascular diseases together
with type 2 diabetes cause 19.5 million deaths annually (WHO noncommunicable disease
report 2018). Most of these deaths are premature and could be prevented by educating
health care providers as well as the public about the benefits of a healthy life style such as
a healthy diet. Given that current global noncommunicable disease prevention strategies
(e.g., WHO Global Action Plan 2013–2020) recommend an increase in fruit and vegetable
consumption, our findings may have important policy implications. Despite recommenda-
tions from several health organizations to increase consumption of fiber-rich foods, fiber
intake worldwide remains well below recommended levels [41]. Recognizing oats as an
additional source of fiber will thus help gain wider socio-political support for establishing
appropriate legislation, preventive strategies, standards, and public recommendations to
combat these major global noncommunicable diseases. Fiber inclusion in traditional and
processed foods is one way to accomplish this [49]. The food industry has aimed to develop
new products geared toward functional foods and ingredients in response to consumer de-
mand for healthier options. Oat and oat beta-glucan could be incorporated into breakfasts,
baking products, milk and meat alternatives [49]. Oats were reported not only for preven-
tion but also for the treatment of T2D. Short term oat interventions were shown to decrease
blood glucose concentrations and to improve insulin sensitivity in patients as early as in
1903 [4]. In series of clinical trials, introduction of low-fat plant-based diets for patients
with type 2 diabetes was shown to improve glycemic control [50]. Therefore, it would be
beneficial to conduct further larger population studies with adequate follow-up duration,
investigating standardized oat intake in a dose-dependent manner, and include oats in the
future as a necessary component of prevention and treatment options for type 2 diabetes
and cardiovascular diseases. Additionally, not all oats are equal in their concentration
of health beneficial compounds or biological effects [51]. Plant breeding efforts and oats
selected for their increased concentration of health beneficial components, or demonstrated
beneficial effects can be supported.
5. Conclusions
Results of this meta-analysis indicate a potential beneficial role of oat consumption
in type 2 diabetes and mortality. However, the evidence is limited and mainly from
observational data, making it difficult to draw firm conclusions. Further detailed work
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with large studies and clinical trials is needed to better characterize these associations and
to assess causality.
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Appendix A. Full Search Strategy per Database
Embase.com
(‘oat’/de OR ‘oat bran’/de OR ‘beta glucan’/de OR ‘whole grain’/de OR (‘avena
sativa’ OR oat OR oats OR oatmeal* OR oatcake* OR porridge* OR muesli OR granola
OR b-glucan* OR β-glucan* OR beta-glucan* OR beta-dextroglucan* OR ‘whole grain*’
OR wholegrain*):ab,ti,kw) AND ((‘cardiovascular disease’/de OR ‘cardiometabolic dis-
ease’/exp OR ‘heart failure’/de OR ‘congestive heart failure’/de OR ‘heart disease’/de
OR ‘hypertensive heart disease’/exp OR ‘hypertensive heart failure’/exp OR ‘coronary
artery disease’/de OR ‘ischemic heart disease’/exp OR ‘cerebrovascular accident’/de OR
‘cerebral artery disease’/de OR ‘atherosclerotic cardiovascular disease’/de OR ‘brain is-
chemia’/exp OR ‘cardiovascular mortality’/de OR ‘mortality’/de OR (((cardiovascular
OR coronar* OR cardiac OR heart OR myocard* OR cardiometabol* OR cardio-metabol*)
NEAR/3 (disease* OR event* OR infarct* OR disorder* OR function* OR dysfunction*
OR health OR mortalit*)) OR cvd OR cvds OR cardiopath* OR angina OR ((vascular OR
‘peripheral arter*’) NEAR/2 disease*) OR ((ischemi* OR ischaemi* OR fail* OR attack* OR
insufficien*) NEAR/3 (heart OR cardia* OR myocard*)) OR (cerebrovascular* NEAR/3
accident*) OR cva OR stroke* OR ((brain OR cerebral) NEAR/3 (ischemi* OR ischaemi*))
OR mortalit*):ab,ti,kw) OR (‘non insulin dependent diabetes mellitus’/exp OR (((diabet*
OR dm) NEAR/3 (‘type 2’ OR type2 OR ‘type ii’ OR ‘non insulin’ OR noninsulin OR ‘adult
onset’ OR ‘slow onset’ OR ‘maturity onset’)) OR T2DM OR dmt2 OR dm2 OR T2-DM
OR dm-t2 OR dm-2 OR niddm OR nid-dm OR MODY):ab,ti,kw)) NOT ([animals]/lim
NOT [humans]/lim) NOT ([Conference Abstract]/lim OR [Letter]/lim OR [Note]/lim OR
[Editorial]/lim)
Medline (Ovid)
(Avena/OR exp beta-Glucans/OR Whole Grains/OR (avena sativa OR oat OR oats OR
oatmeal* OR oatcake* OR porridge* OR muesli OR granola OR b-glucan* OR beta-glucan*
OR beta-dextroglucan* OR whole grain* OR wholegrain*).ab,ti,kw.) AND ((“Cardiovascu-
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lar Diseases”/OR exp “Heart Failure”/OR “Heart Diseases”/OR exp “Coronary Artery
Disease”/OR exp “Myocardial Ischemia”/OR exp “Stroke”/OR “Atherosclerosis”/OR
exp “Brain Ischemia”/OR exp Cerebral Arterial Diseases/OR Mortality/OR mortality.fs.
OR (((cardiovascular OR coronar* OR cardiac OR heart OR myocard* OR cardiometabol*
OR cardio-metabol*) ADJ3 (disease* OR event* OR infarct* OR disorder* OR function* OR
dysfunction* OR health OR mortalit*)) OR cvd OR cvds OR cardiopath* OR angina OR
((vascular OR peripheral arter*) ADJ2 disease*) OR ((ischemi* OR ischaemi* OR fail* OR
attack* OR insufficien*) ADJ3 (heart OR cardia* OR myocard*)) OR (cerebrovascular* ADJ3
accident*) OR cva OR stroke* OR ((brain OR cerebral) ADJ3 (ischemi* OR ischaemi*)) OR
mortalit*).ab,ti,kw.) OR (“Diabetes Mellitus, Type 2”/OR (((diabet* OR dm) ADJ3 (“type 2”
OR type2 OR “type ii” OR “non insulin” OR noninsulin OR “adult onset” OR “slow onset”
OR “maturity onset”)) OR T2DM OR dmt2 OR dm2 OR T2-DM OR dm-t2 OR dm-2 OR
niddm OR nid-dm OR MODY).ab,ti,kw.)) NOT (exp animals/NOT humans/) NOT (letter*
OR news OR comment* OR editorial* OR congres* OR abstract* OR book* OR chapter* OR
dissertation abstract*).pt.
Cochrane Library (Wiley)
((‘avena sativa’ OR oat OR oats OR oatmeal* OR oatcake* OR porridge* OR muesli OR
granola OR b-glucan* OR β-glucan* OR beta-glucan* OR beta-dextroglucan* OR ‘whole
grain*’ OR (whole NEXT grain*) OR wholegrain*):ab,ti,kw) AND ((((cardiovascular OR
coronar* OR cardiac OR heart OR myocard* OR cardiometabol* OR cardio-metabol*)
NEAR/3 (disease* OR event* OR infarct* OR disorder* OR function* OR dysfunction*
OR health OR mortalit*)) OR cvd OR cvds OR cardiopath* OR angina OR ((vascular OR
peripheral NEXT arter*) NEAR/2 disease*) OR ((ischemi* OR ischaemi* OR fail* OR attack*
OR insufficien*) NEAR/3 (heart OR cardia* OR myocard*)) OR (cerebrovascular* NEAR/3
accident*) OR cva OR stroke* OR ((brain OR cerebral) NEAR/3 (ischemi* OR ischaemi*))
OR mortalit*):ab,ti,kw OR (((diabet* OR dm) NEAR/3 (‘type 2’ OR type2 OR ‘type ii’ OR
‘non insulin’ OR noninsulin OR ‘adult onset’ OR ‘slow onset’ OR ‘maturity onset’)) OR
T2DM OR dmt2 OR dm2 OR “T2-DM” OR “dm-t2” OR “dm-2” OR niddm OR “nid-dm”
OR MODY):ab,ti,kw)
Web of Science Core Collection
TS = ((((“avena sativa” OR oat OR oats OR oatmeal* OR oatcake* OR porridge* OR
muesli OR granola OR b-glucan* OR β-glucan* OR beta- glucan* OR beta-dextroglucan*
OR “whole grain*” OR wholegrain*)) AND ((((cardiovascular OR coronar* OR cardiac OR
heart OR myocard* OR cardiometabol* OR cardio-metabol*) NEAR/3 (disease* OR event*
OR infarct* OR disorder* OR function* OR dysfunction* OR health OR mortalit*)) OR
cvd OR cvds OR cardiopath* OR angina OR ((vascular OR “peripheral arter*”) NEAR/2
disease*) OR ((ischemi* OR ischaemi* OR fail* OR attack* OR insufficien*) NEAR/3 (heart
OR cardia* OR myocard*)) OR (cerebrovascular* NEAR/3 accident*) OR cva OR stroke*
OR ((brain OR cerebral) NEAR/3 (ischemi* OR ischaemi*)) OR mortalit*) OR (((diabet* OR
dm) NEAR/3 (“type 2” OR type2 OR “type ii” OR “non insulin” OR noninsulin OR “adult
onset” OR “slow onset” OR “maturity onset”)) OR T2DM OR dmt2 OR dm2 OR “T2- DM”
OR “dm-t2” OR “dm-2” OR niddm OR “nid-dm” OR MODY))) NOT ((animal* OR rat OR
rats OR mouse OR mice OR murine OR nonhuman* OR primate* OR hens) NOT (human*
OR patient*))) AND DT = (article)
Google scholar (first 200 results, out of 23′000)
avena|oat|oats|oatmeal|granola|b-glucan|beta-glucan|“whole grain”|wholegrain|
“whole grains”|wholegrains “cardiovascular|coronary|heart|myocardial|cardiac dis-
ease|failure|mortality”|diabetes|”type 2”|”non insulin”|noninsulin|NIDDM|T2D|mor-
tality trial|study.
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